B. Nicolas Bloch, MD
Associate Professor
Boston University School of Medicine
Dept of Radiology
Breast Imaging

MD, University of Vienna

As a radiologist in an academic medical center, I am devoted to improving clinical care for my patients suffering from breast and prostate cancer. My research has focused on developing new imaging protocols and on correlating prostate and breast cancer imaging phenotypes and MR/US imaging classifiers with histology, immunohistochemistry, and gene expression profiles. I recognize the imperative need for correlating imaging phenotypes with tumor genotypes in order to advance knowledge regarding a broad range of breast and prostate diseases, as well as their early diagnosis, progression/behavior and treatment, by developing new (imaging) biomarkers.
A second major research focus is the design and development of biopsy and treatment tools, like biopsy markers (biopsy clips; Coulter award 2011), and treatment planning phantoms and atlases in collaboration with engineers and image post-processors.

Boston Medical Center
MR Imaging

Boston University School of Medicine
MS Bioimaging Program

Program Director
Boston University School of Medicine
Breast Imaging Fellowship

2015 Boston University: Jorge Soto Researcher of the Year Award - Radiology
2012 Coulter Foundation: Wallace H. Coulter Translational Research Partnership Award
2011 Coulter Foundation: Wallace H. Coulter Translational Research Partnership Award
2008 SCBT/MR: Cum Laude Research Award
2001 National Bank Austria: Austrian National Bank Research Award

Efficacy and safety of gadubutrol 1.0 molar (Gadovist) for breast MRI
01/01/2010 - 12/31/2010 (PI)
Bayer AG

Prostate Cancer Imaging by Combined Ultrasound and Magnetic Resonance Parameters
07/01/2011 - 06/30/2015 (PI)
Riverside Research NIH-NCI

Imaging Phenotypes and Classifiers in Correlation with Tumor Genotypes for Characterization of Breas
01/01/2011 - 12/31/2014 (PI)
Nuclea Biotechnologies

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Chirra P, Leo P, Yim M, Bloch BN, Rastinehad AR, Purysko A, Rosen M, Madabhushi A, Viswanath SE. Multisite evaluation of radiomic feature reproducibility and discriminability for identifying peripheral zone prostate tumors on MRI. J Med Imaging (Bellingham). 2019 Apr; 6(2):024502. PMID: 31259199; DOI: 10.1117/1.JMI.6.2.024502;.
  2. Braman N, Prasanna P, Whitney J, Singh S, Beig N, Etesami M, Bates DDB, Gallagher K, Bloch BN, Vulchi M, Turk P, Bera K, Abraham J, Sikov WM, Somlo G, Harris LN, Gilmore H, Plecha D, Varadan V, Madabhushi A. Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer. JAMA Netw Open. 2019 Apr 05; 2(4):e192561. PMID: 31002322; DOI: 10.1001/jamanetworkopen.2019.2561;.
  3. Lee CL, Dietrich MC, Desai UG, Das A, Yu S, Xiang HF, Jaffe CC, Hirsch AE, Bloch BN. A 3D-Printed Patient-Specific Phantom for External Beam Radiation Therapy of Prostate Cancer. J Eng Sci Med Diagn Ther. 2018 Nov; 1(4).View Related Profiles. PMID: 30775692.
  4. Kan CK, Qureshi MM, Gupta A, Agarwal A, Gignac GA, Bloch BN, Thoreson N, Hirsch AE. Risk factors involved in treatment delays and differences in treatment type for patients with prostate cancer by risk category in an academic safety net hospital. Adv Radiat Oncol. 2018 Apr-Jun; 3(2):181-189.View Related Profiles. PMID: 29904743; DOI: 10.1016/j.adro.2017.12.002;.
  5. Yu H, Scalera J, Khalid M, Touret AS, Bloch N, Li B, Qureshi MM, Soto JA, Anderson SW. Texture analysis as a radiomic marker for differentiating renal tumors. Abdom Radiol (NY). 2017 Oct; 42(10):2470-2478.View Related Profiles. PMID: 28421244; DOI: 10.1007/s00261-017-1144-1;.
  6. Jain A, Khalid M, Qureshi MM, Georgian-Smith D, Kaplan JA, Buch K, Grinstaff MW, Hirsch AE, Hines NL, Anderson SW, Gallagher KM, Bates DDB, Bloch BN. Stereotactic core needle breast biopsy marker migration: An analysis of factors contributing to immediate marker migration. Eur Radiol. 2017 Nov; 27(11):4797-4803.View Related Profiles. PMID: 28526892; DOI: 10.1007/s00330-017-4851-7;.
  7. Xiang HF, Lu HM, Efstathiou JA, Zietman AL, De Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 05; 18(3):37-43.View Related Profiles. PMID: 28407345; DOI: 10.1002/acm2.12063;.
  8. Wan T, Bloch BN, Plecha D, Thompson CL, Gilmore H, Jaffe C, Harris L, Madabhushi A. A Radio-genomics Approach for Identifying High Risk Estrogen Receptor-positive Breast Cancers on DCE-MRI: Preliminary Results in Predicting OncotypeDX Risk Scores. Sci Rep. 2016 Feb 18; 6:21394. PMID: 26887643; PMCID: PMC4757835; DOI: 10.1038/srep21394;.
  9. Kaplan JA, Grinstaff MW, Bloch BN. Polymer film-nanoparticle composites as new multimodality, non-migrating breast biopsy markers. Eur Radiol. 2016 Mar; 26(3):866-73.View Related Profiles. PMID: 26060064; DOI: 10.1007/s00330-015-3852-7;.
  10. Bloch BN, Kuligowska E. Future role of ultrasound and MR imaging in prostate cancer: Editorial Comment on: T. Szopinski, A. Nowicki, F. Zatura, T. Golabek and P. Chlosta Novel trends in transrectal ultrasound imaging of prostate gland carcinoma. J Ultrason. 2015 Mar; 15(60):102-4.View Related Profiles. PMID: 26672493; DOI: 10.15557/JoU.2015.0009;.
Showing 10 of 51 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 51 publications over 15 distinct years, with a maximum of 8 publications in 2013

Contact for Mentoring:

820 Harrison Ave
Boston MA 02118
Google Map

Bloch's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department